Multiple Myeloma

GPRC5D may be a promising therapeutic pathway in the treatment of those with relapsed/refractory multiple myeloma, says Susan Bal, MD.

Data from the phase 1b MonumenTAL-2 trial support pomalidomide plus talquetamab as a promising treatment option in relapsed/refractory multiple myeloma, says Jeffrey Matous, MD.

Following a review of MonumenTAL-1, experts on multiple myeloma discuss the conclusions from the clinical trial and provide their impressions of the findings.

A panel of experts on multiple myeloma discuss dermatologic adverse effects seen in patients receiving talquetamab, including nail toxicities.

An overview of teclistamab in RRMM and the study methodology of using prophylactic tocilizumab to mitigate CRS associated with teclistamab

Sagar Lonial, MD, and Ellen Marin, PA-C, discuss cytokine release syndrome (CRS) and the strategy to manage CRS in their clinic.

The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.

Clinical insights on selecting the right bispecific antibody for the right patient and an overview of barriers seen in community practice.

A panel of experts spoke about the armamentarium of bispecific antibody therapies for patients with relapsed/refractory multiple myeloma and discussed step-up dosing considerations for these approved agents.

Multiple myeloma specialists discuss patient education approaches regarding the management of oral toxicity stemming from talquetamab treatment and outline potential research approaches.

Following a review of oral adverse events, the expert panel discusses how to manage oral toxicities seen in patients with multiple myeloma who are treated with talquetamab.

Clinicians discuss treatment options for advanced-stage multiple myeloma and consider the effects of renal disfunction.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss the conference's most practice-changing data.

Luciano Costa, MD, reviews recent data from the PERSEUS trial investigating the combination of daratumumab, bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients.

An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.

A panel of multiple myeloma specialists discuss emerging data and ongoing research that are informing treating paradigms for patients with multiple myeloma.

Caitlin Costello, MD, discusses her insights and considerations when choosing the next line of therapy in a patient with relapsed/refractory multiple myeloma.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss highlights of the conference in a game show–style production.

A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.

Comprehensive insights on the clinical management of adverse events from talquetamab seen in patients with multiple myeloma, including cytokine release syndrome and infections.

Isatuximab plus carfilzomib, lenalidomide, and dexamethasone demonstrates durable responses in patients with newly diagnosed standard- and high-risk multiple myeloma.

Sagar Lonial, MD, provides an overview of the currently available treatment options in relapsed/refractory multiple myeloma.

The panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.

Key opinion leaders review the management of CAR-T therapy side effects in patients with relapsed/refractory multiple myeloma, including cytokine release syndrome and neurotoxicity, and emphasize the importance of early supervision and known toxicity timing.

Data from the phase 1/2 MonumenTAL-1 studies support flexibility to adjusting the dose of talquetamab in patients with relapsed/refractory multiple myeloma who already have a response.

Because patients with myeloma are at a high risk for financial hardship, study findings support the use of a financial navigation program to reduce financial toxicities of patients.

The expert panel provides clinical insights on the role of CAR T-cell therapy and factors that influence treatment selection in the second line and beyond.

Multiple myeloma specialists outline frailty assessment practices and discuss how frailty informs treatment decisions.

Treatment with anito-cel produces deep, enduring responses in high-risk relapsed/refractory multiple myeloma, says Matthew Frigault, MD.

The safety profile of idecabtagene vicleucel in relapsed/refractory multiple myeloma following the first 3 months of treatment appears to be comparable with standard therapies, says Rachid Baz, MD.